Table 6.

Multivariate analysis using a Cox proportional hazards model for overall and progression free survival in reference group patients.

Variable	Overall survival			Progression-free survival
	P value	HR	95% CI	P value	HR	95% CI
High CD45	0.12	0.986	0.385–2.215	0.89	1.165	0.584–1.863
High CD4	0.46	1.415	0.569–3.520	0.91	0.951	0.379–2.383
High CD8	0.50	0.725	0.284–1.853	0.73	1.082	0.688–1.703
High PD-1	0.13	0.459	0.169–1.246	0.16	1.427	0.873–2.333
High PD-1/CD8	0.23	0.567	0.224–1.437	0.44	1.205	0.753–1.929
Tumor PD-L1 expression	0.38	0.654	0.254–1.685	0.50	1.435	0.498–4.137
Sex (male)	0.63	1.261	0.496–3.207	0.49	1.416	0.534–3.757
Age (≥57)	0.34	1.65	0.592–4.600	0.29	1.771	0.611–5.131
With R/T	0.15	0.47	0.169–1.310	0.03*	0.257	0.079–0.841
With C/T (TMZ)	0.18	0.482	0.166–1.400	0.48	0.696	0.256–1.891
With GKS	0.93	0.959	0.367–2.506	0.63	0.782	0.291–2.099
Without concomitant chemoradiotherapy	0.39	0.572	0.161–2.038	0.58	0.72	0.228–2.272
KPS (≥70)	0.73	1.185	0.460–3.049	0.47	0.692	0.253–1.893
Gross total tumor resection	0.09	0.417	0.150–1.158	0.49	0.713	0.272–1.867
Presence of IHD1 mutation	0.16	7.483	0.467–119.816	0.93	0.907	0.107–7.690
Methylguanine-DNA methyltransferase methylation	0.11	3.404	0.770–15.048	0.59	1.408	0.404–4.908

*P < 0.05.

**P < 0.01.

***P < 0.001.